glp1versus

Byetta vs Foundayo

exenatide (GLP-1 receptor agonist) vs orforglipron (GLP-1 receptor agonist (oral small-molecule)) — a complete side-by-side comparison.

AstraZenecaEli Lilly and Company

Byetta weight loss

2.8%

Foundayo weight loss

12.4%

Byetta dosing

Twice daily (within 60 min before meals)

Foundayo dosing

Once daily

Reviewed by Dr. Elena Vance, DOLast reviewed 7 sources cited

Quick Summary

Byetta (exenatide) and Foundayo (orforglipron) are both glp-1 receptor agonists. In clinical trials, Foundayo showed greater weight loss (12.4% vs 2.8%).

See the comparison table below for detailed side-by-side data.

Byetta vs Foundayo: Full Comparison

FeatureByetta(exenatide)Foundayo(orforglipron)
Active Ingredientexenatideorforglipron
Drug ClassGLP-1 receptor agonistGLP-1 receptor agonist (oral small-molecule)
ManufacturerAstraZenecaEli Lilly and Company
FDA Approved2005-04-282026-04-01
Approved Indications
  • Type 2 diabetes mellitus (adjunct to diet and exercise)
  • Chronic weight management in adults with obesity (BMI >=30 kg/m^2), or overweight (BMI >=27 kg/m^2) with at least one weight-related comorbid condition, as an adjunct to a reduced-calorie diet and increased physical activity
Routesubcutaneous injectionoral
FrequencyTwice daily (within 60 min before meals)Once daily
Starting Dose5 mcg twice daily3 mg once daily
Maintenance Dose10 mcg twice daily12 mg or 36 mg once daily
Max Dose10 mcg twice daily36 mg once daily
Weight Loss (%)2.8%12.4%
A1C Reduction0.8%N/A (not indicated for diabetes)
Key TrialAC2993 Phase 3 (30 weeks)ATTAIN-1 (72 weeks)
List Price$800-$900/monthPricing announced at U.S. launch (April 2026); confirm with LillyDirect
With Insurance$25-$100/month (varies by plan)Formulary coverage evolving; many commercial plans expected to require prior authorization
Savings CardLimited savings programs availableEli Lilly savings program details emerging via LillyDirect

Side Effects: Byetta vs Foundayo

Side EffectByettaFoundayo
Nausea44%21-27%
Vomiting13%10-16%
Diarrhea13%15-20%
Headache9%5-8%
Dizziness9%Not reported
Dyspepsia6%Not reported
Jittery feeling4%Not reported
Pancreatitis (rare)<1%<0.5%
ConstipationNot reported8-14%
Indigestion/dyspepsiaNot reported6-10%
Abdominal painNot reported5-9%
FatigueNot reported4-7%
Hair lossNot reported3-5%

Severity scale: 1 (mild) to 5 (serious). Based on FDA prescribing information and clinical trial data.

Related Comparisons

Byetta vs OzempicFoundayo vs OzempicByetta vs WegovyFoundayo vs WegovyByetta vs MounjaroFoundayo vs MounjaroByetta vs ZepboundFoundayo vs Zepbound

Frequently Asked Questions

Sources & References

FDA & Regulatory

  1. Byetta FDA Drugs@FDA approval record — FDA
  2. Foundayo FDA Drugs@FDA approval record — FDA

Clinical Trial Records

  1. AC2993 Phase 3 clinical trial record — ClinicalTrials.gov
  2. ATTAIN-1 clinical trial record — ClinicalTrials.gov

Peer-Reviewed Literature

  1. DeFronzo RA et al. Effects of Exenatide on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients with Type 2 Diabetes. Diabetes Care 2005;28:1092-1100 — Diabetes Care

Manufacturer Information

  1. Bydureon/Byetta patient website (AstraZeneca) — AstraZeneca

Reference Entries

  1. Exenatide entry on Wikipedia — Wikipedia

This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.